05.04.21

Oculis Announces Financing to Advance Topical Therapies for Posterior and Anterior Segments

Source: Oculis

04.22.21

Ocuphire’s APX3330 for Retinal Diseases to be Presented at ARVO 2021

Source: Ocuphire

04.08.21

Ocuphire Initiates ZETA-1 Phase 2 Clinical Trial Investigating APX3330 in Diabetic Retinopathy

Source: Ocuphire

03.31.21

Outlook Therapeutics Reports Positive Safety Profile from NORSE THREE Study for Lytenava

Source: Outlook Therapeutics

03.01.21

Retinal Therapeutics Development Company Oxular Completes $37 Million (£27 million) Financing

Source: Oxular

02.23.21

Asclepix Therapeutics Partners With Notal Vision on Home OCT Remote Monitoring in DME and AMD Clinical Trials

Source: Asclepix Therapeutics

02.16.21

Kodiak Sciences Announces 1-Year Data from Ongoing Phase 1b Study of KSI-301 in Patients with Retinal Vascular Diseases

Source: Kodiak Sciences

01.05.21

AsclepiX Therapeutics Doses First Patient in Phase 1/2a Trial of AXT107 Intravitreal Self-Forming Gel Depot Peptide for DME

Source: AsclepiX Therapeutics

12.21.20

Genentech’s Faricimab Meets Primary Endpoint and Shows Strong Durability Across Two Global Phase 3 Studies for DME

Source: Genentech

12.15.20

Novartis Reports Positive Topline Results From Second Phase 3 Trial of Beovu in Patients With DME

Source: Novartis

View more stories